Concise review for primary-care physicians a practical guideline for management of hypertension in patients with diabetes

Mayo Clinic Proceedings

Volumn 71, Issue 1, 1996, Pages 53-58

  Fatourechi, Vahab ^a   Kennedy, Frank P ^a   Rizza, Robert A ^a   Hogan, Michael J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; NIFEDIPINE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRAPRIL; THIAZIDE DIURETIC AGENT;

ALCOHOL ABSTINENCE; ALGORITHM; CLINICAL FEATURE; CLINICAL PROTOCOL; DIABETES MELLITUS; DIET RESTRICTION; DRUG CHOICE; EXERCISE; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; REVIEW; SMOKING CESSATION;

EID: 0030041571     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/71.1.53     Document Type: Article

References (37)

1. Fuller JH. Hypertension and diabetes: epidemiologic aspects as a guide to management. J Cardiovasc Pharmacol 1993; 21(Suppl2):S63-S66
2. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153:154-183
3. Ritz E. Hypertension in diabetic nephropathy: prevention and treatment. AmHeartJ 1993; 125:1514-1519
4. Nosadini R, Fioretto P, Trevisan R, Crepaldi G. Insulindependent diabetes mellitus and hypertension. Diabetes Care 1991; 14:210-219
5. Weidmann P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. Diabetes Care 1991; 14:220232
6. Shapiro AP, Benedek TG, Small JL. Effect of thiazides on carbohydrate metabolism in patients with hypertension. N EnglJMed 1961; 265:1028-1033
7. Newman RJ. Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia. BMJ 1976; 2:447-449
8. Rohlfing JJ, Brunzell JD. The effects of diuretics and adrenergic-blocking agents on plasma lipids. West J Med 1986; 145:210-218
9. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319:1517-1525
10. Overlack A, Adamczak M, Bachmann W, Bonner G, Bretzel RG, Derichs R, et al. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. AmJMed 1994; 97:126-134
11. Bain R, Rohde R, Hunsicker LG, McGill J, Kobrin S, Lewis EJ, et al. A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. J Am Soc Nephrol 1992; 3(Suppl4):S97-S103
12. Arauz-Pacheco C, Raskin P. Management of hypertension in diabètes. Endocrinol Metab Clin North Am 1992 Jun; 21:371-394
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition in diabetic nephropathy. NEnglJMed 1993; 329:1456-1462
14. Ferrier C, Ferrari P, Weidmann P, Keller U, Beretta-Piccoli C, Riesen WF. Antihypertensive therapy with Ca2+: antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care 1991; 14:911-914
15. Caldwell BV. Treating hypertension in the diabetic patient: therapeutic goals and the role of calcium channel blockers. ClinTher 1993; 15:618-636
16. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med 1994; 154:1185-1202
17. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1995; 18(Suppl 1):9-15
18. Dawson KG, McKenzie JK, Ross SA, Chiasson J-L, Hamet P. Report of the Canadian Hypertension Society Consensus Conference. 5. Hypertension and diabetes. Can Med Assoc J 1993; 149:821-826
19. Bottini PB, Prisant LM, Carr AA. Automated blood pressure monitoring: should it be used routinely in managing hypertension? Postgrad Med 1994 May 1; 95:89-90; 93-94; 96; 101-102; 106-108
20. Sunman W, Sever PS. Non-angiotensin effects of angiotensin-converting enzyme inhibitors [edtiorial]. Clin Sei 1993; 85:661-670
21. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75:793795
22. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994; 96:451456
23. Psaty BM, Heckbert SR, Koepsell TD, Siscovik DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620-625
24. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested [edtiorial]. JAMA 1995; 274:654-655
25. Lenfant C. The calcium channel blocker scare: lessons for the future. Circulation 1995; 91:2855-2856
26. Mimran A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouze J. Contrasting effects of captopril and nifedipine in normotensive patients with insipient diabetic nephropathy. J Hypertens 1988; 6:919-923
27. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991; 302:210-216
28. Materson BJ, Reda DJ, Cushman WC, Massie BM, Fries ED, Kochar MS, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328:914-921
29. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992; 6:175-179
30. Shionoiri H, Ueda S, Gotoh E, Ito T, Ogihara T. Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients. J Cardiovasc Pharmacol 1990; 16:905-909
31. Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with noninsulin dependent diabetes mellitus. J Hum Hypertens 1989; 3:35-39
32. Janka H-U, Mehnert H. Isradipine-a dihydropyridine calcium antagonist with a favorable metabolic profile in hypertensive type II diabetics compared to nifedipine [abstract]. J Cardiovasc Pharmacol 1988; 12(Suppl 6):S213
33. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330:1852-1857
34. Warram JH, Laffel LMB, Valsania P, Christlieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991; 151:1350-1356
35. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264
36. Huapponen R, Lehtonen A, Vahatalo M. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol 1992; 43:365368
37. Feher MD. Doxazosin therapy in the treatment of diabetic hypertension. Am Heart J 1991; 121:1294-1301